Clicky

Silence Therapeutics Plc(SLN)

Description: Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.


Keywords: Biology Molecular Biology Acid Gene Expression Proprietary Technology Genome Molecular Genetics Nucleic Acids RNA Rna Interference Small Interfering Rna Gene Silencing Silence Therapeutics

Home Page: www.silence-therapeutics.com

SLN Technical Analysis

72 Hammersmith Road
London, W14 8TH
United Kingdom
Phone: 44 20 3457 6900


Officers

Name Title
Mr. Craig A. Tooman M.B.A., MBA Pres, CEO & Exec. Director
Ms. Rhonda L. Hellums Chief Financial Officer
Dr. Giles V. Campion M.D. Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
Ms. Gem Gokmen Hopkins Head of IR & Corp. Communications
Dr. John Strafford Ph.D. Sr. VP of Bus. Devel., Alliance Management & New Product Devel.
Mr. Jørgen Wittendorff Sr. VP & Head of Manufacturing
Dr. Barbara A. Ruskin J.D., Ph.D. Sr. VP and Chief Intellectual Property & Innovation Officer
Dr. Eric Floyd Ph.D. Sr. VP of Regulatory Affairs & Quality Assurance
Dr. Marie Wikstrom Lindholm Ph.D. Sr. VP & Head of Molecular Design

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 12.7858
Price-to-Sales TTM: 31.6706
IPO Date: 2020-09-08
Fiscal Year End: December
Full Time Employees: 105
Back to stocks